cystic fibrosis with Pseudomonas aeruginosa infection
Respiratory · 2011–2013
7decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tobramycin Management of a proven Pseudomonas aeruginosa infection in a patient aged 6 years or older with cystic fibrosis. | Mar 2013 | Not recommended | unclear |
| tobramycin Treatment of Pseudomonas aeruginosa infection in patients aged 6 years or older with cystic fibrosis. | Nov 2013 | Recommended with restriction | input received |
| aztreonam Management of proven Pseudomonas aeruginosa infection in patients with cystic fibrosis. | Jul 2012 | Recommended with restriction | no section in document |
| aztreonam Management of proven Pseudomonas aeruginosa infection in patients with cystic fibrosis. | Jul 2012 | Recommended with restriction | no section in document |
| colistimethate sodium Treatment of colonisation and infections of the lung due to susceptible Pseudomonas aeruginosa in patients with cystic fibrosis, used as short-term therapy for… | Mar 2011 | Recommended with restriction | unclear |
| colistimethate sodium Treatment of colonisation and infections of the lung due to susceptible Pseudomonas aeruginosa in patients with cystic fibrosis, for both early/intermittent… | Mar 2011 | Recommended with restriction | unclear |
| tobramycin Management of proven Pseudomonas aeruginosa infection in patients with cystic fibrosis. | Mar 2011 | Recommended with restriction | unclear |
What the PBS pays
$4M in government benefit over 2024–25, across 8,360 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tobramycin | $2.1M |
| tobramycin, solution for inhalation | $2.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.